Analysts have been eager to weigh in on the Healthcare sector with new ratings on Addus Homecare (ADUS – Research Report), Pfizer (PFE – Research Report) and Cardinal Health (CAH – Research Report).
Pfizer (PFE)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer, with a price target of $28.00. The company’s shares closed last Monday at $26.26, close to its 52-week low of $25.23.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.57, which is a 21.4% upside from current levels. In a report issued on April 10, Berenberg Bank also maintained a Hold rating on the stock with a $27.00 price target.
Cardinal Health (CAH)
In a report released yesterday, Steve Baxter from Wells Fargo maintained a Sell rating on Cardinal Health, with a price target of $96.00. The company’s shares closed last Monday at $102.83.
According to TipRanks.com, Baxter is a 3-star analyst with an average return of
Currently, the analyst consensus on Cardinal Health is a Moderate Buy with an average price target of $115.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADUS:
- Addus HomeCare price target raised to $115 from $110 at Stephens
- Addus HomeCare price target raised to $115 from $108 at BofA
- Addus HomeCare initiated with an Equal Weight at Barclays
- Addus Homecare Unveils Year-End Financial Performance
- Addus HomeCare CEO ‘optimistic’ about acquisition opportunities in 2024
